US and UK Finalize No-Tariff Deal on Pharmaceuticals.
Britain and America have signed a key trade agreement that will preserve zero duties on British medicine exports entering the American market.
The Terms of the Deal
As part of the deal, the UK has committed to increase funding on medicines through the National Health Service (NHS). This move guarantees that import taxes on these key exports will stay at nothing for a period of the next three years.
This development is in response to earlier threats to hike import taxes on branded drug products, with figures mentioned reaching 100%.
"This agreement with the UK bolsters the worldwide climate for new treatments and introduces much-needed equity to U.S.–U.K. medicine commerce," an announcement declared.
Economic Importance
Drugs constitute one of the Britain's largest export categories to the US, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period prior to last September, the UK shipped medicines totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This agreement secures work, boosts capital expenditure and paves the way for the UK to become a worldwide center for medical research," a government official remarked.
Specific UK Commitments
The deal involves several specific commitments from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to increase total public funding on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be limited at 15%. Previously, repayments topped 20%.
Recent Tensions
The deal follows a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
The disagreement were exacerbated by claims that US patients were paying a premium for the equivalent treatments than people in the other developed nations.
Recently, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar expansions have been directed toward projects in the United States.
A senior figure acknowledged that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the previous ten-year period.